Recent advances in the treatment of polycythemia vera

References

• Silver R. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988;332(8607):403.
   Google Scholar
• Seewann HL, Zikulnig R, Gallhofer G, et al. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b. Eur J Cancer Clin Oncol. 1991;27:S58–S63.
   Google Scholar
• Taylor P, Dolan G, Ng JP, et al. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br J Haematol. 1996;92(1):55–59.
   PubMed Web of Science ®Google Scholar
• Heis N, Rintelen C, Gisslinger B, et al. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol. 2009;62(1):27–31.
   Google Scholar
• Foa P, Massaro P, Ribera S, et al. Role of interferon alpha-2a in the treatment of polycythemia vera. Am J Hematol. 1995;48(1):55–57.
   PubMed Web of Science ®Google Scholar
• Cimino R, Rametta V, Matera C, et al. Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am J Hematol. 1993;44(3):155–157.
   PubMed Web of Science ®Google Scholar
• Finelli C, Gugliotta L, Gamberi B, et al. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol. 1993;43(4):316–318.
   PubMed Web of Science ®Google Scholar
• DE Wolf JM, Hendriks D, Egger R, et al. α-interferon for intractable pruritus in polycythaemia vera. Lancet. 1991;337(8735):241.
   PubMed Web of Science ®Google Scholar
• Peschel C, Aulitzky WE, Huber C. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment-impact on treatment of myeloproliferative disorders. Leuk Lymphoma. 1996;22(Suppl 1):129–134.
   PubMedGoogle Scholar
• Litam PP, Landaw SA, Zamkoff KW. Efficacy of alpha interferon and hydroxyurea in late phase refractory myeloproliferative disease. Haematologia. 1994;26(2):87–90.
   PubMedGoogle Scholar
• Dudley JM, Westwood N, Woodcock S, et al. Sensitivity of erythroid progenitors to recombinant growth factors in the diagnosis of myeloproliferative disorders. Int J Cell Cloning. 1990;8(Suppl 1):199–202.
   PubMedGoogle Scholar
• Dudley JM, Westwood N, Leonard S, et al. Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol. 1990;75(2):188–194.
   PubMed Web of Science ®Google Scholar
• Hino M, Futami E, Okuno S, et al. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol. 1993;66(3):161–162.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Leoni P, Liberati M, et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol. 1994;68(5):247–250.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian HM, Giles F, et al. Pegylated interferon therapy for patients with philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost. 2006;32(4 Pt 2):409–416.
   PubMed Web of Science ®Google Scholar
• Kiladjian J-J, Cassinat B, Turlure P, et al. PVN1: a phase 2 study of pegylated interferon-α2a in polycythemia vera (PV) by the ‘PV-Nord’ group. Preliminary report of efficacy and safety. Blood. 2005;106(11):4940.
   Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037–2040.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065–3072.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418–5424.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology. 2009;14(6):331–334.
   PubMed Web of Science ®Google Scholar
• Lu M, Zhang W, Li Y, et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010;38(6):472–480.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498–1509.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized, phase 3, trial of interferon-α versus hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022. Online ahead of print.
   Web of Science ®Google Scholar
• Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–1769.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–e208.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175–e184.
   PubMed Web of Science ®Google Scholar
• Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35(9):2592–2601.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012;18(11):3008–3014.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):e226–e237.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88–99.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97(9):1591–1600.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455–1457.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, COMFORT-II investigators, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–4053.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701–1707.
   PubMed Web of Science ®Google Scholar
• Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017;176(1):76–85.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Sadjadian P, Wille K, Griesshammer M. Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations. Cancers. 2020;12(11):3132.
   PubMed Web of Science ®Google Scholar
• Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75(11):2187–2199.
   PubMed Web of Science ®Google Scholar
• Sant'Antonio E, Bonifacio M, Breccia M, et al. A journey through infectious risk associated with ruxolitinib. Br J Haematol. 2019;187(3):286–295.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35(2):485–493.
   PubMed Web of Science ®Google Scholar
• https://www.hematology.org/covid-19/covid-19-and-myeloproliferative-neoplasms. Accessed 9 March 2022.
   Google Scholar
• Cattaneo D, Bucelli C, Cavallaro F, et al. Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience. Blood Cancer J. 2021;11(11):185.
   PubMed Web of Science ®Google Scholar
• Coltoff A, Mesa R, Gotlib J, et al. Real-World outcomes of ruxolitinib treatment for polycythemia vera. Clin Lymphoma Myeloma Leuk. 2020;20(10):697–703.e1.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Bartoletti D, Andriani A, et al. Efficacy and safety of ruxolitinib in the treatment of elderly patients with policythemia vera resistant/intolerant to hydroxyurea. Blood. 2021;138(Supplement 1):2581–2581.
   Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093.
   PubMed Web of Science ®Google Scholar
• Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105–2116.
   PubMed Web of Science ®Google Scholar
• Ginzburg Y, Kirubamoorthy K, Salleh S, et al. Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy. Blood. 2021;138(Supplement 1):390–390.
   Google Scholar
• Verstovsek S, Kuykendall AT, Hoffman R, et al. A phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera. Blood. 2021;138(Supplement 1):1504–1504.
   PubMedGoogle Scholar
• Konopleva M, Martinelli G, Daver N, et al. MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020;34(11):2858–2874.
   PubMed Web of Science ®Google Scholar
• Kubesova B, Pavlova S, Malcikova J, et al. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia. 2018;32(2):450–461.
   PubMed Web of Science ®Google Scholar
• Lu M, Wang X, Li Y, et al. Combination treatment in vitro with nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120(15):3098–3105.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Lu M, Kosiorek H, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134(6):525–533.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Iurlo A, Vannucchi AM, et al. Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Blood Cancer J. 2021;11(3):53.
   Google Scholar